(SNT) Synektik S.A. - Ratings and Ratios
Exchange: WAR • Country: Poland • Currency: PLN • Type: Common Stock • ISIN: PLSNKTK00019
SNT: Medical Equipment, IT Solutions, Radiopharmaceutical Products
Synektik S.A., a Poland-based company, specializes in delivering a comprehensive range of products, services, and IT solutions tailored to the needs of surgery, diagnostic imaging, and nuclear medicine applications. Their product portfolio encompasses medical equipment utilized in both diagnostics and therapy, as well as nuclear medicine, catering to the diverse requirements of healthcare professionals. By focusing on these areas, Synektik S.A. plays a significant role in enhancing patient care and outcomes in Poland.
One of the key areas of focus for Synektik S.A. is the development of innovative IT solutions designed specifically for radiology. These solutions aim to improve the efficiency and accuracy of diagnostic processes, ultimately contributing to better patient care. Additionally, the company is engaged in the research, production, and sale of radiopharmaceutical products, which are crucial in the diagnosis of oncology. This multifaceted approach underscores Synektik S.A.'s commitment to advancing medical technology and healthcare services.
Beyond its product and service offerings, Synektik S.A. operates a dedicated research laboratory focused on diagnostic imaging systems. This laboratory serves as a hub for innovation, where the company's experts work on developing and refining diagnostic imaging technologies. Furthermore, Synektik S.A. runs a service center for medical equipment, providing maintenance services, acceptance tests, and specialist tests. These services are essential for ensuring that medical equipment functions optimally, thereby supporting the delivery of high-quality patient care.
Founded in 2001 and headquartered in Warsaw, Poland, Synektik S.A. has established itself as a significant player in the country's healthcare sector. With its web presence at https://www.synektik.com.pl, the company provides easy access to information about its products, services, and initiatives. Listed with the ISIN PLSNKTK00019, Synektik S.A.'s common stock falls under the GICS Sub Industry category of Health Care Equipment, reflecting its specialized focus on medical technology and equipment.
Additional Sources for SNT Stock
SNT Stock Overview
| Market Cap in USD | 415m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
SNT Stock Ratings
| Growth 5y | 94.8% |
| Fundamental | 41.5% |
| Dividend | 70.0% |
| Rel. Strength Industry | 5190 |
| Analysts | - |
| Fair Price Momentum | 352.85 PLN |
| Fair Price DCF | 281.02 PLN |
SNT Dividends
| Dividend Yield 12m | 1.30% |
| Yield on Cost 5y | 23.42% |
| Annual Growth 5y | 53.12% |
| Payout Consistency | 82.5% |
SNT Growth Ratios
| Growth Correlation 3m | 64.3% |
| Growth Correlation 12m | 87.2% |
| Growth Correlation 5y | 89% |
| CAGR 5y | 78.68% |
| CAGR/Mean DD 5y | 4.90 |
| Sharpe Ratio 12m | 2.40 |
| Alpha | 166.55 |
| Beta | 0.41 |
| Volatility | 41.81% |
| Current Volume | 29.7k |
| Average Volume 20d | 23.7k |
As of January 22, 2025, the stock is trading at PLN 233.50 with a total of 29,687 shares traded.
Over the past week, the price has changed by +10.66%, over one month by +22.25%, over three months by +27.60% and over the past year by +177.25%.
Partly, yes. Based on ValueRay Fundamental Analyses, Synektik S.A. (WAR:SNT) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 41.53 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SNT as of January 2025 is 352.85. This means that SNT is currently undervalued and has a potential upside of +51.11% (Margin of Safety).
Synektik S.A. has no consensus analysts rating.
According to ValueRays Forecast Model, SNT Synektik S.A. will be worth about 384.7 in January 2026. The stock is currently trading at 233.50. This means that the stock has a potential upside of +64.76%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 209.1 | -10.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 384.7 | 64.8% |